Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India. In the domestic market, Intas enjoys leadership position in chronic therapies such as Neurology, Psychiatry, Cardiovasculars, Diabetes, Oncology, Urology, Nephrology, Rheumatology & Gynecology, Infertility, Gastroenterology, Pain Management and healthy presence in other major therapeutic segments. Besides well-established domestic prominence, Intas is also present in more than 80 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries. Intas' global strategy includes alliances with leading Global Pharma Companies for development and distribution of products as well as direct product distribution. The company is known for its range of products in Oncology and other hospital based therapeutic segments in the EU and US. After the landmark acquisition of Teva's assets, Intas has become a leading player in the generics market in the UK.